Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
BioVersys is a clinical-stage biotech company focused on developing antimicrobial therapies to address unmet medical needs in infectious diseases, including tuberculosis and hospital-acquired infections. The company targets infectious disease indications with next-generation antimicrobial treatments.
2 investors
BiOWiSH develops microbial-based biotechnology solutions for agriculture, aquaculture, and environmental management to improve soil health, crop yields, and sustainable food production. The company serves farmers and agricultural institutions globally with scientifically validated biological products.
2 investors
Bioworks develops PlaX, a plant-based fiber intended as an alternative to petroleum-derived synthetic fibers, aimed at making the apparel industry more sustainable. The company targets clothing and textile manufacturers seeking lower-impact materials.
2 investors
Bioyond develops intelligent laboratory automation platforms and robotic systems for experimental research environments, including vision systems and scheduling software.
2 investors
Birch Biosciences develops enzyme-based plastic recycling technologies using green chemistry and machine learning to transform plastic waste into reusable material. The company targets the plastic resin market with solutions for industrial and commercial recycling applications.
2 investors
Bitrobius develops gene therapy technologies, specifically the Gentrafix platform, leveraging microbial molecular biology and genetic engineering. The company serves therapeutic applications in areas including neurodegeneration and drug discovery.
2 investors
Blueprint Genetics is a genetic testing company that combines laboratory science, genetics, and bioinformatics to analyze and interpret genetic data. It operates as a global company with in-house software, cloud, and bioinformatics teams supporting its testing services.
2 investors
Bluestem Biosciences uses an industrial fermentation process with an engineered yeast strain to convert American corn into 3-hydroxypropionic acid (3-HP) and other platform chemicals, offering a domestic alternative to petroleum-based production. Its business model retrofits existing U.S. bioethanol facilities to produce these chemicals at commercial scale, targeting American manufacturing and agricultural supply chains.</parameter> <parameter name="founders">[]
2 investors
2 investors
Bolt Threads was a manufacturer of biomaterials for personal care formulations. The company is no longer operating.
2 investors
BoneSupport develops synthetic bone graft substitutes that remodel to match patient bone and elute antibiotics to prevent infection during healing. The products serve orthopedic surgeons and patients undergoing bone void procedures.
2 investors
Bonito develops encoded library and live-cell selection technologies to discover delivery ligands, generating high signal-to-noise data on membrane-bound targets to train AI models for precision drug delivery. The company combines functional selections with AI to turn physical delivery experiments into programmable ligand discovery.
2 investors
Bontia Bio is a synthetic biology company that uses proprietary fermentation technology to create natural bioactive compounds for animal health and agriculture, with its first product targeting fleas and ticks in companion animals.
2 investors
Botalys develops a platform for creating rare botanical ingredients tailored for nutraceutical and cosmetic applications through structured co-development partnerships with industry leaders. The platform guides partners through plant selection, validation, sourcing, cultivation, and industrial-scale production of specialized botanical ingredients.
2 investors
BrainsGate develops a neurostimulation therapy for stroke patients based on stimulation of the sphenopalatine ganglion (SPG) to increase cerebral blood flow. The company operates in the medical device field, having conducted the ImpACT-24 clinical studies for acute ischemic stroke treatment.
2 investors
BrainSpec develops software for analyzing and visualizing MR spectroscopy (MRS) neuroimaging data, aiming to make a non-invasive "virtual biopsy" available to clinicians and researchers. Its technology targets patient populations with conditions such as brain tumors, Alzheimer's disease, and Multiple Sclerosis.
2 investors
Breaking develops engineered microorganisms and enzymes—notably a microbe variant called MICROBE X-32—that biologically degrade many types of plastic waste into organic matter. The company also aims to create new bioplastics, chemical recycling via depolymerization, and biofuels/biomaterials, addressing plastic pollution and remediation.
2 investors
Miist develops inhaled microparticle therapeutics that deliver medicine to the bloodstream in 30 seconds, targeting conditions like migraine, pain, and anxiety where rapid onset is critical. The company is advancing a portfolio of systemic therapies starting with MST-02, a migraine treatment designed to work significantly faster than existing oral medications.
2 investors
BreezeBio develops a programmable platform called NanoGalaxy for targeted delivery of genetic medicines, aiming to move genetic payloads to specific cells and tissues. The company operates in the biotech and genetic therapeutics space.
2 investors
Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery. Its pipeline includes BT-267, a brain-penetrant LRRK2 inhibitor, and BT-409, an NLRP3 inflammasome inhibitor.
2 investors
Bright Biotech produces recombinant proteins, including growth factors, by expressing them in plant chloroplasts. Its proteins are aimed at cell culture and regenerative medicine applications.
2 investors
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform. The company operates in the immuno-oncology drug development space.
2 investors
Wireless urologic sensing system for lower urinary tract symptoms such as incontinence, prostate issues, and neurogenic bladder.
2 investors
Bright Angel Therapeutics is a pre-clinical stage biotechnology company developing small-molecule antifungal therapeutics aimed at drug-resistant and life-threatening invasive fungal infections. It designs fungal-selective inhibitors targeting fungal stress responses, using Schrödinger's computational drug discovery platform alongside its own proprietary technologies.
2 investors